Lisa Butler

Professor Lisa Butler

Cancer Council Principal Research Fellow

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Professor Lisa Butler is a Cancer Council SA Beat Cancer Principal Cancer Research Fellow in the Freemasons Centre for Male Health and Wellbeing (FCMHW) and the Adelaide Medical School at the University of Adelaide, and heads the Prostate Cancer Research Group at the South Australian Health and Medical Research Institute (SAHMRI). She holds key executive positions in the FCMHW, the Australian Prostate Cancer BioResource, the Prostate Cancer Foundation of Australia and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Prof Butler has established an internationally-recognised research program focused on targeting androgen signalling in prostate cancer, discovering innovative biomarkers of response to treatment, and testing the efficacy of novel drugs for prostate cancer.

 

Prof Butler undertook postdoctoral studies at Memorial Sloan-Kettering Cancer Center in New York from 1998-2001. Her work there directly contributed to the clinical development of histone deacetylase inhibitors as anticancer agents and formed the basis of her interests in translational research. Since returning to Australia, a major focus of her research program has been the development of preclinical models that more closely represent the individual responses in men with prostate cancer. She developed the unique ex vivo tumor culture model, which has been applied to multiple tissues and resulted in the adoption of the technique by scientists from the University of Leuven, Belgium, Thomas Jefferson University, Philadelphia, UT Southwestern, Dallas and the Royal Marsden Hospital, London. Prof Butler’s research group has used this model to demonstrate the anti-proliferative efficacy of the novel heat shock protein 90 inhibitor AUY922 and the cyclin dependent kinase inhibitor ribociclib in prostate cancer tissues (Clin Cancer Res 18:3562), and funding was subsequently awarded by Cancer Australia in 2013 to translate these preclinical studies into an ongoing clinical trial of ribociclib for prostate cancer. From 2015-21 she has led a Movember Revolutionary Team to investigate the role of lipids in prostate cancer and their potential for new biomarkers of disease aggressiveness, and in 2019 she and her collaborators were awarded funding from the US Department of Defense to further study the role of lipid metabolising enzymes in prostate cancer. Her other major research interests include development of novel combinatorial strategies to target the androgen receptor and lipid metabolism pathways in prostate cancer.

    Expand
  • Appointments

    Date Position Institution name
    2018 Cancer Council Principal Research Fellow University of Adelaide
    2014 - 2018 Australian Research Council Future Fellow University of Adelaide
    2012 - 2013 University Senior Research Fellow University of Adelaide
    2008 - 2012 Cancer Council SA Senior Research Fellow University of Adelaide
    2006 - 2008 Florey Research Fellow University of Adelaide
    2003 - 2005 Prostate Cancer Foundation of Australia Research Fellow University of Adelaide
    2002 - 2002 NHMRC Senior Research Officer University of Adelaide
    2001 - 2001 NHMRC Senior Research Officer Flinders University
  • Awards and Achievements

    Date Type Title Institution Name Country Amount
    2021 Award Women in Leadership Award Cancer Council SA Beat Cancer Project Australia $60,000
    2011 Nomination Nominated Delegate, NHMRC 75th Anniversary Symposium National Health and Medical Research Council Australia
    2004 Honour The Governor’s Leadership Foundation of South Australia The Governor’s Leadership Foundation of South Australia Australia
    2003 Award ILEX Oncology Scholar-in-Training Award American Association for Cancer Research United States
    2002 Award Bio-Rad New Investigator Award Australian Society for Medical Research Australia
    2001 Award Gerald B. Grindey Scholar In Training Award American Association for Cancer Research United States
    1997 Award AMRAD Young Investigator Award Australian Society for Medical Research Australia
    1996 Award The Ross Wishart Memorial Award Australian Society for Medical Research Australia
    1994 Award The R.F. Whelan Prize The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia
    1994 Award Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Prize The University of Adelaide Australia
  • Education

    Date Institution name Country Title
    1995 - 1998 University of Adelaide Australia PhD
    1994 - 1994 University of Adelaide Australia BSC (Hons)
    1991 - 1993 University of Adelaide Australia BSc
  • Postgraduate Training

    Date Title Institution Country
    1998 - 2001 Postdoctoral Fellow Memorial Sloan Kettering Cancer Center, New York United States
  • Research Interests

    Expand
  • Journals

    Year Citation
    2021 Tieu, T., Irani, S., Bremert, K. L., Ryan, N. K., Wojnilowicz, M., Helm, M., . . . Cifuentes-Rius, A. (2021). Patient-derived prostate cancer explants: a clinically relevant model to assess siRNA-based nanomedicines. Advanced Healthcare Materials, 10(6), 2001594-1-2001594-11.
    DOI Scopus1 WoS2
    2021 Kwan, K. H., Burvenich, I. J. G., Centenera, M. M., Goh, Y. W., Rigopoulos, A., Dehairs, J., . . . Ackermann, U. (2021). Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear medicine and biology, 93, 37-45.
    DOI
    2021 Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A. A., Yeung, N., . . . Horvath, L. G. (2021). Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 24(3), 860-870.
    DOI Scopus1 WoS1 Europe PMC1
    2021 Gillis, J. L., Hinneh, J. A., Ryan, N., Irani, S., Moldovan, M., Quek, L. E., . . . Butler, L. M. (2021). A feedback loop between the 1 androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth: Cooperativity between 6PGD and AR drives prostate cancer growth. eLife, 10, 27 pages.
    DOI Europe PMC1
    2021 Hoy, A. J., Nagarajan, S. R., & Butler, L. M. (2021). Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nature Reviews Cancer, 14 pages.
    DOI
    2021 Fernandes, R. C., Toubia, J., Townley, S., Hanson, A. R., Dredge, B. K., Pillman, K. A., . . . Selth, L. A. (2021). Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer. Cell Reports, 34(1), 1-17.
    DOI Scopus3 WoS3
    2021 Nagarajan, S. R., Butler, L. M., & Hoy, A. J. (2021). The diversity and breadth of cancer cell fatty acid metabolism.. Cancer Metab, 9(1), 1-28.
    DOI WoS7 Europe PMC6
    2021 Kokkinos, J., Sharbeen, G., Haghighi, K. S., Ignacio, R. M. C., Kopecky, C., Gonzales-Aloy, E., . . . Phillips, P. A. (2021). Ex vivo culture of intact human patient derived pancreatic tumour tissue.. Sci Rep, 11(1), 1-15.
    DOI Scopus3 WoS3 Europe PMC1
    2021 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.. Cancer research, canres.3863.2020.
    DOI Europe PMC1
    2021 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zininos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718.
    DOI Scopus7 WoS7 Europe PMC5
    2021 Truong, J. X. M., Spotbeen, X., White, J., Swinnen, J. V., Butler, L. M., Snel, M. F., & Trim, P. J. (2021). Removal of optimal cutting temperature (O.C.T.) compound from embedded tissue for MALDI imaging of lipids. Analytical and Bioanalytical Chemistry, 413(10), 2695-2708.
    DOI Scopus2 WoS2
    2020 Kobayashi, H., Gieniec, K. A., Wright, J. A., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. L. (2020). The Balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis. Gastroenterology, 160(4), 1224-1239.
    DOI Scopus8 WoS8 Europe PMC8
    2020 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2020). Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibition. Molecular cancer research : MCR, 18(10), 1500-1511.
    DOI Scopus2 WoS2 Europe PMC1
    2020 Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., . . . Butler, L. M. (2020). Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife, 9, 1-34.
    DOI Scopus16 WoS17 Europe PMC11
    2020 Butler, L., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., . . . Swinnen, J. V. (2020). Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.. Advanced drug delivery reviews, 159, 245-293.
    DOI Scopus36 WoS28 Europe PMC21
    2020 Hollis, B., Day, F. R., Busch, A. S., Thompson, D. J., Soares, A. L. G., Timmers, P. R. H. J., . . . Vacic, V. (2020). Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. Nature Communications, 11(1), 1536.
    DOI Scopus8 Europe PMC3
    2020 Wu, Y., Xie, J., Xin, J., Lenchine, R. V., Wang, X., Fang, M. D., . . . Proud, C. G. (2020). eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA. Biochemical Journal, 477(22), 4367-4381.
    DOI Scopus3 WoS3
    2020 Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2020). Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Open, 10(1), 6 pages.
    DOI Scopus5 WoS5 Europe PMC3
    2020 Jankovic-Karasoulos, T., Bianco-Miotto, T., Butler, M. S., Butler, L. M., McNeil, C. M., O'Toole, S. A., . . . Ricciardelli, C. (2020). Elevated levels of tumor apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 76(7), 976-987.
    DOI Scopus4 WoS4 Europe PMC3
    2020 Mah, C. Y., Nassar, Z. D., Swinnen, J. V., & Butler, L. M. (2020). Lipogenic effects of androgen signaling in normal and malignant prostate. Asian Journal of Urology, 7(3), 258-270.
    DOI Scopus9 Europe PMC2
    2020 Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., . . . Proud, C. G. (2020). Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.. Cellular and molecular life sciences : CMLS, 78(1), 249-270.
    DOI Scopus6 WoS6 Europe PMC4
    2020 Owen, K. L., Gearing, L. J., Zanker, D. J., Brockwell, N. K., Khoo, W. H., Roden, D. L., . . . Parker, B. S. (2020). Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone.. EMBO Rep, 21(6), e50162.
    DOI Scopus19 WoS12 Europe PMC14
    2020 Shirazi, H. S., Chan, K. M., Rouget, J., Ostrikov, K., McNicholas, K., Li, J., . . . MacGregor, M. (2020). Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells.. Biointerphases, 15(3), 031002.
    DOI Scopus6 WoS5 Europe PMC3
    2020 Miladinovic, D., Cusick, T., Mahon, K. L., Haynes, A. -M., Cortie, C. H., Meyer, B. J., . . . Hoy, A. J. (2020). Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer.. Cancers (Basel), 12(6), 1-19.
    DOI Scopus3 WoS3 Europe PMC1
    2019 Johnson, I. R. D., Sorvina, A., Logan, J. M., Moore, C. R., Heatlie, J. K., Parkinson-Lawrence, E. J., . . . Brooks, D. A. (2019). A paradigm in immunochemistry, revealed by monoclonal antibodies to spatially distinct epitopes on Syntenin-1. International Journal of Molecular Sciences, 20(23), 6035-1-6035-16.
    DOI
    2019 Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2019). Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Molecular Cancer Research, 17(4), 949-962.
    DOI Scopus26 WoS25 Europe PMC18
    2019 Zadra, G., Ribeiro, C. F., Chetta, P., Ho, Y., Cacciatore, S., Gao, X., . . . Loda, M. (2019). Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 116(2), 631-640.
    DOI Scopus74 WoS78 Europe PMC49
    2019 Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Ranu, H. (2019). Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1). Nature Communications, 10(1), 5 pages.
    DOI Scopus1 WoS1 Europe PMC2
    2019 Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. G. (2019). An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 144(5), 1151-1159.
    DOI Scopus6 WoS6 Europe PMC1
    2019 Mutuku, S. M., Trim, P. J., Prabhala, B. K., Irani, S., Bremert, K. L., Logan, J. M., . . . Butler, L. M. (2019). Evaluation of small molecule drug uptake in patient-derived prostate cancer explants by mass spectrometry. Scientific Reports, 9(1), 15008.
    DOI Scopus6 WoS6 Europe PMC3
    2019 Irani, Y. D., Pulford, E., Mortimer, L., Irani, S., Butler, L., Klebe, S., & Williams, K. A. (2019). Sex differences in corneal neovascularization in response to superficial corneal cautery in the rat. PLoS ONE, 14(9), e0221566-1-e0221566-17.
    DOI Scopus1 WoS1 Europe PMC1
    2019 Tieu, T., Dhawan, S., Haridas, V., Butler, L. M., Thissen, H., Cifuentes-Rius, A., & Voelcker, N. H. (2019). Maximizing RNA loading for gene silencing using porous silicon nanoparticles. ACS Applied Materials and Interfaces, 11(26), 22993-23005.
    DOI Scopus7 WoS8 Europe PMC1
    2019 Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019). Cancer-associated fibroblasts—heroes or villains?. British Journal of Cancer, 121(4), 293-302.
    DOI Scopus59 WoS54 Europe PMC38
    2018 McClurg, U. L., McCracken, S. R., Butler, L., Riabowol, K. T., & Binda, O. (2018). Ex vivo culture and lentiviral transduction of Benign Prostatic Hyperplasia (BPH) samples. Bio-protocols, 8(21), e3075-.
    DOI Europe PMC1
    2018 Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Butler, L. (2018). Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 9(1), 4616-1-4616-11.
    DOI Scopus22 WoS25 Europe PMC23
    2018 Nguyen, E., Centenera, M., Moldovan, M., Das, R., Irani, S., Vincent, A., . . . Butler, L. (2018). Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants. Molecular & cellular proteomics : MCP, 17(8), 1470-1486.
    DOI Scopus18 WoS19 Europe PMC8
    2018 Dadaev, T., Saunders, E., Newcombe, P., Anokian, E., Leongamornlert, D., Brook, M., . . . Sellers, T. (2018). Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 9(1), 19 pages.
    DOI Scopus44 WoS40 Europe PMC39
    2018 Aref, A., Vincent, A. D., O'Callaghan, M., Martin, S., Sutherland, P., Hoy, A., . . . Wittert, G. (2018). The inverse relationship between prostate specific antigen (PSA) and obesity. Endocrine-Related Cancer, 25(11), 933-941.
    DOI Scopus9 WoS8 Europe PMC6
    2018 Shafi, A., Schiewer, M., de Leeuw, R., Dlygeri, E., McCue, P., Shah, N., . . . Knudsen, K. (2018). Novel patient derived models reveal the impact of the tumor microenvironment on therapeutic response. European Urology Oncology, 1(4), 325-337.
    DOI Scopus17 WoS18 Europe PMC16
    2018 Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., . . . Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622.
    DOI Scopus36 WoS38 Europe PMC29
    2018 Su, Y., Chim, S., Zhou, L., Hassanshahi, M., Chung, R., Fan, C., . . . Xian, C. (2018). Osteoblast derived-neurotrophin‑3 induces cartilage removal proteases and osteoclast-mediated function at injured growth plate in rats. Bone, 116, 232-247.
    DOI Scopus8 WoS7 Europe PMC2
    2018 Lin, H., Lee, B., Castillo, L., Spielman, C., Grogan, J., Yeung, N., . . . Daly, R. (2018). Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. The Prostate, 78(4), 308-317.
    DOI Scopus18 WoS22 Europe PMC14
    2018 Armstrong, H., Gillis, J., Johnson, I., Nassar, Z., Moldovan, M., Levrier, C., . . . Butler, L. (2018). Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Scientific reports, 8(1), 2090-1-2090-14.
    DOI Scopus9 WoS11 Europe PMC6
    2018 McClurg, U., Nabbi, A., Ricordel, C., Korolchuk, S., McCracken, S., Heer, R., . . . Binda, O. (2018). Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. British journal of cancer, 118(5), 713-726.
    DOI Scopus13 WoS15 Europe PMC11
    2018 Nassar, Z., Aref, A., Miladinovic, D., Mah, C., Raj, G., Hoy, A., & Butler, L. (2018). Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU International, 121(Suppl. 3), 9-21.
    DOI Scopus29 WoS26 Europe PMC16
    2018 Cifuentes-Rius, A., Butler, L., & Voelcker, N. (2018). Precision nanomedicines for prostate cancer. Nanomedicine, 13(8), 803-807.
    DOI Scopus4 WoS4 Europe PMC1
    2018 Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L., Leung, S., McNeil, C., . . . Tilley, W. (2018). The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clinical Cancer Research, 24(10), 2328-2341.
    DOI Scopus31 WoS29 Europe PMC19
    2018 Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19.
    DOI Scopus17 WoS15 Europe PMC12
    2017 Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., . . . Selth, L. A. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77(4), 1021-1034.
    DOI Scopus64 WoS69 Europe PMC43
    2017 Tran, L., Kichenadasse, G., Butler, L., Centenera, M., Morel, K., Ormsby, R., . . . Sykes, P. (2017). The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Molecular cancer therapeutics, 16(12), 2689-2700.
    DOI Scopus17 WoS15 Europe PMC8
    2017 Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34.
    DOI Scopus63 WoS66 Europe PMC43
    2016 Xie, J., Mølck, C., Paquet-Fifield, S., Butler, L., Sloan, E., Ventura, S., & Hollande, F. (2016). High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgenindependent prostate cancer cells. Oncotarget, 7(28), 44492-44504.
    DOI Scopus9 WoS9 Europe PMC6
    2016 Philp, L., Day, T., Butler, M., Laven-Law, G., Jindal, S., Hickey, T., . . . Tilley, W. (2016). Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) ablation limits offspring viability and growth in mice. Scientific Reports, 6(1), 28950-1-28950-14.
    DOI Scopus7 WoS7 Europe PMC5
    2016 Armstrong, H., Koay, Y., Irani, S., Das, R., Nassar, Z., The Australian Prostate Cancer BioResource., . . . Butler, L. (2016). A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumor cells without induction of a heat shock response. Prostate, 76(16), 1546-1559.
    DOI Scopus15 WoS14 Europe PMC10
    2016 Butler, L., Centenera, M., & Swinnen, J. (2016). Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocrine-Related Cancer, 23(5), 219-227.
    DOI Scopus46 WoS45 Europe PMC28
    2016 Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13.
    DOI Scopus8 WoS8 Europe PMC5
    2016 Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page.
    DOI Europe PMC1
    2015 Johnson, I., Parkinson-Lawrence, E., Keegan, H., Spillane, C., Barry-O'Crowley, J., Watson, W., . . . Brooks, D. (2015). Endosomal gene expression: a new indicator for prostate cancer patient prognosis?. Oncotarget, 6(35), 37919-37929.
    DOI Scopus17 WoS15 Europe PMC12
    2015 Centenera, M., Carter, S., Gillis, J., Marrocco-Tallarigo, D., Grose, R., Tilley, W., & Butler, L. (2015). Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 22(5), 805-818.
    DOI Scopus15 WoS14 Europe PMC10
    2015 Butler, L., Ferraldeschi, R., Armstrong, H., Centenera, M., & Workman, P. (2015). Maximizing the therapeutic potential of HSP90 inhibitors. Molecular Cancer Research, 13(11), 1445-1451.
    DOI Scopus105 WoS107 Europe PMC79
    2014 Johnson, I., Parkinson-Lawrence, E., Butler, L., & Brooks, D. (2014). Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers. Prostate, 74(5), 547-560.
    DOI Scopus10 WoS9 Europe PMC7
    2014 Johnson, I., Parkinson-Lawrence, E., Shandala, T., Weigert, R., Butler, L., & Brooks, D. (2014). Altered endosome biogenesis in prostate cancer has biomarker potential. Molecular Cancer Research, 12(12), 1851-1862.
    DOI Scopus17 WoS19 Europe PMC14
    2014 Selth, L. A., Roberts, M. J., Chow, C. W. K., Marshall, V. R., Doi, S. A. R., Vincent, A. D., . . . Gardiner, R. A. (2014). Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 21(4), L17-L21.
    DOI Scopus27 WoS25 Europe PMC22
    2014 Tarulli, G. A., Butler, L. M., Tilley, W. D., & Hickey, T. E. (2014). Bringing androgens up a NOTCH in breast cancer. Endocrine-Related Cancer, 21(4), T183-T202.
    DOI Scopus22 WoS21 Europe PMC16
    2014 Ochnik, A., Moore, N., Jankovic-Karasoulos, T., Bianco-Miotto, T., Ryan, N., Thomas, M., . . . Hickey, T. (2014). Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause, 21(1), 79-88.
    DOI Scopus11 WoS9 Europe PMC8
    2014 Bianco-Miotto, T., Trotta, A., Need, E., Lee, A., Ochnik, A., Giorgio, L., . . . Buchanan, G. (2014). Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and Delta(4)-tibolone. Molecular and Cellular Endocrinology, 382(2), 899-908.
    DOI Scopus3 WoS1 Europe PMC1
    2014 Rodrigues, D., Butler, L., Estelles, D., & de Bono, J. (2014). Molecular pathology and prostate cancer therapeutics: from biology to bedside. Journal of Pathology, 232(2), 178-184.
    DOI Scopus30 WoS27 Europe PMC18
    2013 Comstock, C., Augello, M., Goodwin, J., de Leeuw, R., Schiewer, M., Ostrander, W., . . . Knudsen, K. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491.
    DOI Scopus76 WoS72 Europe PMC55
    2013 Philp, L., Butler, M., Hickey, T., Butler, L., Tilley, W., & Day, T. (2013). SGTA: A new player in the molecular co-chaperone game. Hormones and Cancer, 4(6), 343-357.
    DOI Scopus19 WoS20 Europe PMC16
    2013 Trotta, A., Need, E., Selth, L., Chopra, S., Pinnock, C., Leach, D., . . . Buchanan, G. (2013). Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812-2823.
    DOI Scopus16 WoS16 Europe PMC14
    2013 Centenera, M., Raj, G., Knudsen, K., Tilley, W., & Butler, L. (2013). Ex vivo culture of human prostate tissue and drug development. Nature Reviews, Urology, 10(8), 483-487.
    DOI Scopus82 WoS85 Europe PMC69
    2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650.
    DOI Scopus94 WoS98 Europe PMC74
    2013 Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704.
    DOI Scopus42 WoS41 Europe PMC33
    2013 Abankwa, D., Millard, S., Martel, N., Choong, C., Yang, M., Butler, L., . . . Leong, G. (2013). Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochemistry, 14(10), 1-9.
    DOI Scopus12 WoS11 Europe PMC10
    2013 Ravindranathan, P., Lee, T., Yang, L., Centenera, M., Butler, L., Tilley, W., . . . Raj, G. (2013). Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nature Communications, 4(5), 1923-1-1923-11.
    DOI Scopus94 WoS94 Europe PMC69
    2013 Centenera, M., Fitzpatrick, A., Tilley, W., & Butler, L. (2013). Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1835(2), 211-218.
    DOI Scopus36 WoS35 Europe PMC22
    2013 Chiam, K., Ryan, N., Ricciardelli, C., Day, T., Buchanan, G., Ochnik, A., . . . Bianco-Miotto, T. (2013). Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 73(2), 182-193.
    DOI Scopus12 WoS11 Europe PMC10
    2012 Betterman, K., Paquet- Fifield, S., Asselin-Labat, M., Visvader, J., Butler, L., Stacker, S., . . . Harvey, N. (2012). Remodeling of the lymphatic vasculature during mouse mammary gland morphogenesis is mediated via epithelial-derived lymphangiogenic stimuli. American Journal of Pathology, 181(6), 2225-2238.
    DOI Scopus13 WoS14 Europe PMC12
    2012 Trotta, A., Need, E., Butler, L., Selth, L., O'Loughlin, M., Coetzee, G., . . . Buchanan, G. (2012). Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Journal of Molecular Endocrinology, 49(2), 57-68.
    DOI Scopus18 WoS17 Europe PMC16
    2012 Moore, N., Buchanan, G., Harris, J., Selth, L., Bianco-Miotto, T., Hanson, A., . . . Tilley, W. (2012). An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 19(4), 599-613.
    DOI Scopus39 WoS37 Europe PMC26
    2012 Selth, L., Tilley, W., & Butler, L. (2012). Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 19(4), 99-113.
    DOI Scopus33 WoS31 Europe PMC24
    2012 Dean, J., McClendon, A., Hickey, T., Butler, L., Tilley, W., Witkiewicz, A., & Knudsen, E. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle, 11(14), 2756-2761.
    DOI Scopus151 WoS147 Europe PMC112
    2012 Centenera, M., Gillis, J., Hanson, A., Jindal, S., Taylor, R., Risbridger, G., . . . Butler, L. (2012). Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research, 18(13), 3562-3570.
    DOI Scopus79 WoS80 Europe PMC64
    2012 Moore, N., Hickey, T., Butler, L., & Tilley, W. (2012). Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology, 357(1-2), 60-70.
    DOI Scopus28 WoS29 Europe PMC16
    2012 Thompson, V., Day, T., Bianco-Miotto, T., Selth, L., Han, G., Thomas, M., . . . Tilley, W. (2012). A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 131(3), 662-672.
    DOI Scopus22 WoS22 Europe PMC17
    2012 Selth, L., Townley, S., Gillis, J., Ochnik, A., Murti, K., Macfarlane, R., . . . Butler, L. (2012). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 131(3), 652-661.
    DOI Scopus136 WoS129 Europe PMC101
    2012 Schiewer, M., Goodwin, J., Han, S., Brenner, J., Augello, M., Dean, J., . . . Knudsen, K. (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery, 2(12), 1134-1149.
    DOI Scopus210 WoS215 Europe PMC171
    2011 Chiam, K., Centenera, M., Butler, L., Tilley, W., & Bianco-Miotto, T. (2011). GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One, 6(9), e25634-1-e25634-11.
    DOI Scopus36 WoS31 Europe PMC29
    2011 Peters, A., Ingman, W., Tilley, W., & Butler, L. (2011). Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. Endocrinology, 152(10), 3728-3737.
    DOI Scopus47 WoS42 Europe PMC35
    2011 Buchanan, G., Need, E., Barrett, J., Bianco-Miotto, T., Thompson, V., Butler, L., . . . Coetzee, G. (2011). Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Molecular and Cellular Endocrinology, 342(1-2), 20-31.
    DOI Scopus9 WoS10 Europe PMC8
    2010 Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., . . . Ricciardelli, C. (2010). Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiology Biomarkers & Prevention, 19(10), 2611-2622.
    DOI Scopus104 WoS92 Europe PMC65
    2010 Ochnik, A. M., Jankovic-Karasoulos, T., Cops, E. J., Birrell, S. N., Butler, L. M., Jindall, S., . . . Hickey, T. E. (2010). Medroxyprogesterone acetate impedes 5 alpha-dihydrotesterone induced androgen receptor signaling in normal and malignant human breast epithelial cells. Cancer Research, 70(Suppl 8), 4 pages.
    DOI
    2010 Murti, K., Butler, L., Sakko, A., Ricciardelli, C., Mitto, T., Octnick, A., . . . Tilley, W. (2010). Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 19(1), 5-13.
    DOI Scopus2
    2009 Marrocco, D., Centenera, M., Scher, H., Tilley, W., & Butler, L. (2009). Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2(6), 619-630.
    DOI Scopus4 Europe PMC4
    2009 Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J., . . . Tilley, W. (2009). Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research, 69(15), 6131-6140.
    DOI Scopus269 WoS260 Europe PMC179
    2009 Chiam, K., Tilley, W., Butler, L., & Bianco-Miotto, T. (2009). The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochimica et Biophysica Acta-Reviews on Cancer, 1795(2), 104-109.
    DOI Scopus14 WoS15 Europe PMC10
    2008 Centenera, M., Harris, J., Tilley, W., & Butler, L. (2008). The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 22(11), 2373-2382.
    DOI Scopus100 WoS93 Europe PMC69
    2008 Cops, E., Bianco-Miotto, T., Moore, N., Clarke, C., Birrell, S., Butler, L., & Tilley, W. (2008). Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology, 110(3-5), 236-243.
    DOI Scopus53 WoS52 Europe PMC40
    2007 Buchanan, G., Ricciardelli, C., Harris, J., Prescott, J., Yu, Z., Jia, L., . . . Tilley, W. (2007). Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine-rich tetratricopeptide repeat containing protein α. Cancer Research, 67(20), 10087-10096.
    DOI Scopus76 WoS74 Europe PMC59
    2007 Birrell, S., Butler, L., Harris, J., Buchanan, G., & Tilley, W. (2007). Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB Journal, 21(10), 2285-2293.
    DOI Scopus74 WoS64 Europe PMC50
    2007 Robzyk, K., Oen, H., Buchanan, G., Butler, L., Tilley, W., Mandal, A., . . . Caplan, A. (2007). Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Molecular and Cellular Endocrinology, 268(1-2), 67-74.
    DOI Scopus8 WoS10 Europe PMC7
    2007 Marrocco, D., Tilley, W., Bianco-Miotto, T., Evdokiou, A., Scher, H., Rifkind, R., . . . Butler, L. (2007). Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics, 6(1), 51-60.
    DOI Scopus81 WoS76 Europe PMC64
    2006 Butler, L., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thai, L., . . . Evdokiou, A. (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 119(4), 944-954.
    DOI Scopus63 WoS60 Europe PMC45
    2006 Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024.
    DOI Scopus15 WoS14 Europe PMC10
    2005 Buchanan, G., Birrell, S., Peters, A., Bianco-Miotto, T., Ramsay, K., Cops, E., . . . Tilley, W. (2005). Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Research, 65(18), 8487-8496.
    DOI Scopus59 WoS58 Europe PMC46
    2005 Shen, H., Buchanan, G., Butler, L., Prescott, J., Henderson, M., Tilley, W., & Coetzee, G. (2005). GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.. Journal of Biological Chemistry, 386(1), 69-74.
    DOI Scopus25 WoS25 Europe PMC17
    2005 Wold, R. S., Lopez, S. T., Yau, C. L., Butler, L. M., Pareo-Tubbeh, S. L., Waters, D. L., . . . Baumgartner, R. N. (2005). Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. Journal of the American Dietetic Association, 105(1), 54-63.
    DOI Scopus79
    2004 Wayne, S. J., Lopez, S. T., Butler, L. M., Baumgartner, K. B., Baumgartner, R. N., & Ballard-Barbash, R. (2004). Changes in dietary intake after diagnosis of breast cancer. Journal of the American Dietetic Association, 104(10), 1561-1568.
    DOI Scopus67 Europe PMC47
    2004 Scher, H., Buchanan, G., Gerald, W., Butler, L., & Tilley, W. (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 11(3), 459-476.
    DOI Scopus196 WoS190 Europe PMC138
    2003 Kutko, M., Glick, R., Butler, L., Coffey, D., Rifkind, R., Marks, P., . . . LaQuaglia, M. (2003). Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clinical Cancer Research, 9(15), 5749-5755.
    Scopus50 WoS50 Europe PMC32
    2002 Butler, L., Zhou, X., Marks, P., Rifkind, R., & Richon, V. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the United States of America, 99(18), 11700-11705.
    DOI Scopus442 WoS434 Europe PMC308
    2001 Butler, L., Webb, Y., Agus, D., Higgins, B., Tolentino, T., Kutko, M., . . . Marks, P. (2001). Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clinical Cancer Research, 7(4), 962-970.
    Scopus119 WoS112 Europe PMC59
    2001 Babidge, W., Butler, L., Burton, M., & Cowled, P. (2001). Methylation of CpG sites in exon 2 of the Bcl-2 gene occurs in colorectal carcinoma. Anticancer Research, 21(4A), 2809-2814.
    Scopus14 WoS12 Europe PMC9
    2001 Coffey, D., Kutko, M., Glick, R., Butler, L., Heller, G., Rifkind, R., . . . LaQuaglia, M. (2001). The histone deacetylase inhibitor CBHA inhibits growth of human neuroblastoma xenografts in vivo alone and synergistically with all-trans retinoic acid. Cancer Research, 61(9), 3591-3594.
    Scopus144 WoS141 Europe PMC77
    2000 Butler, L., Dobrovic, A., Bianco-Miotto, T., & Cowled, P. (2000). Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. British Journal of Cancer, 82(1), 131-135.
    DOI Scopus20 WoS18 Europe PMC21
    2000 Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., . . . Richon, V. M. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research, 60(18), 5165-5170.
    Scopus572 WoS554 Europe PMC363
    2000 Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L., Rifkind, R., . . . LaQuaglia, M. P. (2000). Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Medical and Pediatric Oncology, 35(6), 577-581.
    DOI Scopus58 WoS58 Europe PMC31
    1999 Butler, L., Hewett, P., Fitridge, R., & Cowled, P. (1999). Deregulation of apoptosis in colorectal carcinoma: theoretical and therapeutic implications. Australian and New Zealand Journal of Surgery, 69(2), 88-94.
    DOI Scopus42 WoS41 Europe PMC27
    1999 Leonardos, L., Butler, L., Hewett, P., Zalewski, P., & Cowled, P. (1999). The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma.. Cancer Letters, 143(1), 29-35.
    DOI Scopus19 WoS15 Europe PMC12
    1998 Butler, L., Hewett, P., Butler, W., & Cowled, P. (1998). Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. British Journal of Cancer, 77(9), 1454-1459.
    DOI Scopus40 WoS38 Europe PMC28
    1997 Harkin, L., Butler, L., & Burcham, P. (1997). Role of G-T transversions in the mutagenicity of alkylperoxyl radicals: induction of alkali-labile sites in bacteriophage M13 mp19.. Chemical Research in Toxicology, 10(5), 575-581.
    DOI Scopus17 WoS17 Europe PMC4
    Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M. M., . . . Butler, L. M. (n.d.). DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
    DOI
  • Book Chapters

    Year Citation
    2014 Moore, N., Centenera, M., Butler, L., Hickey, T., & Tilley, W. (2014). Androgens and the androgen receptor (AR). In E. Gelmann, C. Sawyers, & F. Rauscher (Eds.), Molecular oncology: Causes of cancer and targets for treatment (1 ed., pp. 378-391). Cambridge, United Kingdom: Cambridge University Press.
    DOI
    2013 Selth, L., Townley, S., Gillis, J., Tilley, W., & Butler, L. (2013). Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease. In T. Ochiya (Ed.), Circulating MicroRNAs. Methods and Protocols (Vol. 1024, pp. 235-246). UK: Springer.
    DOI Scopus3 Europe PMC3
    2013 Selth, L. A., Townley, S. L., Gillis, J. L., Tilley, W. D., & Butler, L. M. (2013). Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. In Methods in Molecular Biology (pp. 235-246). Humana Press.
    DOI
    2009 Buchanan, G., Need, E., Bianco-Miotto, T., Greenberg, N., Scher, H., Centenera, M., . . . Tilley, W. (2009). Insights from AR gene mutations. In D. Tindall, & J. Mohler (Eds.), Androgen action in prostate cancer (pp. 207-240). Dordrecht, Netherlands: Springer.
    DOI Scopus4
  • Conference Papers

    Year Citation
    2017 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
    DOI
    2017 Shafi, A. A., Schiewer, M. J., de Leeuw, R., McCue, P. A., Gomella, L. G., Lallas, C. D., . . . Knudsen, K. E. (2017). PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
    DOI
    2017 Tran, L. N. K., Kichenadasse, G., Ormsby, R. J., Morel, K. L., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2017). COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. In JOURNAL OF UROLOGY Vol. 197 (pp. E1108-E1109). Boston, MA: ELSEVIER SCIENCE INC.
    DOI
    2016 Tran, L. N. K., Kichenadasse, G., Morel, K. L., Ormsby, R. J., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2016). Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling. In CANCER RESEARCH Vol. 76 (pp. 4 pages). New Orleans, LA: AMER ASSOC CANCER RESEARCH.
    2016 Oesterreich, S., Katz, T., Logan, G., Levine, K., Nagle, A., Huo, Z., . . . Butler, L. (2016). Potential role of prolactin signaling in development and growth of the lobular subtype of breast cancer. In CANCER RESEARCH Vol. 76 (pp. 1 page). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
    DOI
    2016 Jankowitz, R., McAuliffe, P., Sikora, M., Butler, L., Ahrendt, G., Johnson, R., . . . Oesterreich, S. (2016). A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma. In CANCER RESEARCH Vol. 76 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
    DOI
    2015 Johnson, I. R. D., Parkinson-Lawrence, E. J., Butler, L. M., O'Leary, J. J., & Brooks, D. A. (2015). Altered Endosome Biogenesis in Prostate Cancer Has Prognostic Potential. In JOURNAL OF PATHOLOGY Vol. 237 (pp. S17). Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL.
    2012 Ochnik, A. M., Moore, N. L., Birrell, S. N., Butler, L. M., Jindal, S., Selth, L., . . . Hickey, T. E. (2012). The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. In Cancer Research Vol. 72 (pp. 2). Chicago, IL: American Association for Cancer Research.
    DOI
    2009 Lee, M., Labrinidis, A., Liapis, V., Hay, S., Zinonos, I., Butler, L., . . . Evdokiou, A. (2009). The histone deacetylase inhibitor, LBH589 blocks osteoclastogenesis, enhances osteoblast activity and reduces tumor burden in bone. In CANCER RESEARCH Vol. 69 (pp. 1 page). AMER ASSOC CANCER RESEARCH.
    2009 Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research.
    2006 Murphy, N., Bianco-Miotto, T., Ricciardelli, C., Ruiz, A., Segara, D., McNeil, C., . . . Tilley, W. (2006). Expression of the androgen receptor and its association with disease outcome in breast cancer. In Breast Cancer Research and Treatment Vol. 100 (pp. S262-S263). San Antonio, Texas: Springer.
    2005 Evdokiou, A., Minh, L. T., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., . . . Findlay, D. M. (2005). Apo2L/TRAIL is a potent anticancer agent that prevents breast cancer-induced bone destruction in a mouse model. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. P35). Bethesda, MD: AMER SOC BONE & MINERAL RES.
  • Conference Items

    Year Citation
    2020 Gieniec, K., Kobayashi, H., Lannagan, T., Wang, T., Asai, N., Mizutani, Y., . . . Worthley, D. (2020). Melanoma cell adhesion molecule defines a proliferative subset of leptin receptor-lineage cells that substantially contribute to the colorectal cancer stroma. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.
    2020 Kobayashi, H., Gieniec, K., Wright, J., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. (2020). Stromal imbalance of bone morphogenetic protein signaling drives colorectal carcinogenesis. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.
    2020 Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
    2020 Horvath, L. G., Lin, H. -M., Mak, B., Mahon, K., Yeung, N., Docanto, M., . . . Butler, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
    DOI
    2020 Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
    DOI
    2020 Mah, C. Y., Nassar, Z. D., Burvenich, I. J., Irani, S., Centenera, M. M., Moldovan, M., . . . Butler, L. M. (2020). DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
    DOI
    2019 Shafi, A. A., Schiewer, M. J., de Leeuw, R., Dylgjeri, E., Mccue, P. A., Shah, N., . . . Knudsen, K. E. (2019). Patient derived models reveal impact of the tumor microenvironment on therapeutic response. Poster session presented at the meeting of CANCER RESEARCH. Atlanta, GA: AMER ASSOC CANCER RESEARCH.
    DOI
    2019 Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2019). Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
    2019 Butler, L., Irani, S., Centenera, M., Ryan, N., Pegg, N., & Brooks, A. N. (2019). Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
    DOI WoS2
    2018 Mutuku, S. M., Centenera, M. M., Trim, P. J., Snel, M. F., & Butler, L. M. (2018). Evaluation of small molecule drug uptake in ex vivo cultured clinical prostate tumours by mass spectrometry. Poster session presented at the meeting of BJU INTERNATIONAL. Brisbane, AUSTRALIA: WILEY.
    2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley.
    2018 Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
    2018 Butler, L. M. (2018). New Insights into Prostate Tumour Heterogeneity from Studying the "Lipidome". Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
    2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Sydney: Wiley.
    2018 Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S. B., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Poster session presented at the meeting of Journal of Clinical Oncology. San Francisco, CA: American Society of Clinical Oncology.
    DOI
    2017 Mutuku, S. M., Centenera, M., Trim, P., Gustafsson, O. J., Snel, M., & Butler, L. (2017). A Mass Spectrometry Approach to Characterise Lipid Composition in Prostate Tumuors. Poster session presented at the meeting of 11th Florey Postgraduate Research Conference. Adelaide.
    2017 Aref, A., Vincent, A., O'Callaghan, M., Hoy, A., Butler, L., & Wittert, G. (2017). The inverse relationship between prostate specific antigen (PSA) and obesity in healthy men; support for a hormonal, rather than haemodilution mechanism. Poster session presented at the meeting of Abstracts of the 2017 ANZUP Annual Scientific Meeting, as published in Asia-Pacific Journal Of Clinical Oncology. Melbourne, VIC: Wiley.
    DOI
    2017 Mutuku, S. M., Prabhala Bala., Centenera, M., Trim, P., Snel, M., & Butler, L. (2017). Quantification of Enzalutamide in Cultured Prostate Tissue Using LC-MS/MS. Poster session presented at the meeting of 26th Australian and New Zealand Society for Mass Spectrometry. Flinders University.
    2017 Butler, L. (2017). IDENTIFICATION OF DRUG RESPONSE BIOMARKERS IN PATIENT-DERIVED PROSTATE EXPLANTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
    2016 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
    2015 Johnson, I. R. D., Parkinson-Lawrence, E. J., Brooks, D. A., Butler, L., & O'Leary, J. J. (2015). Altered Endosome Biogenesis in Prostate Cancer Identifies Potential Diagnostic Biomarkers. Poster session presented at the meeting of JOURNAL OF PATHOLOGY. Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL.
    2015 Armstrong, H., Butler, L., Selth, L., Tarulli, G., & Centenera, M. (2015). The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization. Poster session presented at the meeting of BJU INTERNATIONAL. Cairns, AUSTRALIA: WILEY-BLACKWELL.
    2014 Roberts, M., Selth, L., Chow, C., Doi, S., Vincent, A., Butler, L., . . . Gardiner, R. (2014). Seminal fluid microRNAs: new, non-invasive biomarkers for prostate cancer. Poster session presented at the meeting of BJU International. Brisbane: Wiley.
    2014 Zhang, A. Y., Butler, L. M., Stricker, P. D., Kench, J. G., Tilley, W. D., Sebastian, L., . . . Horvath, L. (2014). Pharmacodynamic effects of the heat shock protein 90 (HSP90) inhibitor, AUY922, in high-risk, localised prostate cancer. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
    DOI WoS1
    2014 Philp, L. K., Day, T. K., Butler, M. S., Jindal, S., Butler, L. M., & Tilley, W. D. (2014). Full, but Not Partial, Sgta Ablation Confers Subfertility and Limits Offspring Viability and Growth in Mice. Poster session presented at the meeting of ENDOCRINE REVIEWS. ENDOCRINE SOC.
    2014 Zhuang., Rodriguez Lopez., Chiam, K., Harryanto, H., Ryan, N., Jindal, S., . . . Bianco-Miotto. (2014). A high fat diet early in life and prostate cancer risk. Poster session presented at the meeting of The Australian Health and Medical Research Congress. Melbourne, Australia.
    2013 Philp, L., Day, T., Jindal, S., Pickering, M., Butler, L., & Tilley, W. (2013). Protein expression alterations in a unique gleason prostate cancer progression cohort. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
    2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). CIRCULATING microRNAs PREDICT BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
    2012 Butler, L. M. (2012). DEVELOPMENTAL THERAPEUTICS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
    2010 Centenera, M., Treloar, J., Hanson, A., Sutherland, P., Tilley, W., & Butler, L. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier.
    DOI
    2008 Hickey, T., Ocknik, A., Bianco-Miotto, T., Birrell, S., Butler, L., & Tilley, W. (2008). Functional androgen signaling in an explant model of normal human breast tissue. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press.
    DOI
    2006 Buchanan, G., Ricciardelli, C., Prescott, J., Harris, J. M., Yu, Z. C. -L., Jia, L., . . . Tilley, W. D. (2006). αSGT: A critical determinant of androgen receptor function in prostate cancer. Poster session presented at the meeting of Cancer Research. Washington, DC: American Association for Cancer Research.
  • Patents

    Year Citation
    2020 Brooks, D., Parkinson-Lawrence, E., Johnson, I., & Butler, L. (2020). 15/794,270, Methods for detecting prostate cancer by determining the ratio of early to late endosomal markers. United States.
    2020 Brooks, D., O'Leary, J., Logan, J., Sorvina, A., Martino, C., Johnson, I., . . . Butler, L. (2020). PCT/AU2020/050925, Methods for Confirming Detection and Evaluating the Progression of a Prostate Cancer - II. Australia.
    2014 Brooks, D., Parkinson-Lawrence, E., Johnson, I., Butler, L., & Weigert, R. (2014). PCT/AU2014/000612, Methods for detecting prostate cancer. Australia.
    2003 Richon, V., Marks, P., Rifkind, R., & Butler, L. (2003). WO/2003/070188, Method of treating TRX mediated inflammatory diseases. United States Patent US2003235588.

CURRENT FELLOWSHIP

  • Cancer Council of SA Beat Cancer Principal Research Fellowship. BUTLER LM. From bedside to bench to bedside: improving prognosis and treatment of prostate cancer. 2018-2021. $600,000.

 

PREVIOUS FELLOWSHIPS

  • Australian Research Council Future Fellowship. BUTLER LM. Molecular hallmarks of androgen receptor targeting in prostate cancer. 2014-2018. $846,240.
  • Cancer Council of SA Senior Research Fellowship. BUTLER LM. Androgen Signalling in the normal human breast: role and implications for breast cancer risk. 2008-2012. $276,000.
  • Royal Adelaide Hospital/IMVS Florey Research Fellowship. BUTLER LM. The role of androgen receptor signalling in the normal human breast. 2006-2008. $237,180.
  • Prostate Cancer Foundation of Australia Postdoctoral Fellowship. BUTLER LM. Dominant negative androgen receptors: a novel strategy for treatment of advanced prostate cancer. 2003-2005. $300,000.

 

CURRENT GRANTS

  • Cancer Council of SA Women in Leadership Award. BUTLER LM. 2021. $59,976.
  • The Hospital Research Foundation Prostate Cancer Project Grant. Centenera MM, BUTLER LM, Horvath LG. A patient-derived discovery platform for companion biomarker development in prostate cancer. 2021-2022. $149,662.
  • The Hospital Research Foundation Prostate Cancer Project Grant. Nassar ZD, Xie J, BUTLER LM, Selth LA. Targeting Fatty Acid Oxidation for Treatment of High Risk Localised Prostate Cancer. 2021-2022. $149,956.
  • Medical Research Future Fund Biomedical Translation Bridge (MTP Connect) / Envision Sciences Pty. Ltd./University of South Australia.  Brooks DA, O’Leary JJ, Pursey P, Morretti K, Klebe S, Samaratunga H, Delahunt B, Karageorgos L, Esterman A, Dinan A, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER  L, Ung B Diagnosis and prognosis of prostate cancer using blood and tissue tests. 2020-21. $2,400,000.
  • Tour de Cure Project Grant. Holst J, BUTLER LM. A new therapy targeting “gluttonous” prostate cancer cells. 2020-2021. $200,000.
  • US Department of Defense Prostate Cancer Research Program Idea Development Award. Loda M, BUTLER LM, Swinnen JV. Lipid elongation via ELOVL5: a novel target for advanced prostate cancer. 2019-2022. $USD 736,817.
  • UniSA Division of Health Sciences and UniSA Innovation Services. Brooks DA, Logan J, Martino C, Sorvina A, Johnson I, BUTLER L, Selemidis S, O’Leary J, Pursey P. UniSA Support Grant for Cancer Research Translation Programme. 2019-2022. $1,632,000.
  • Cancer Australia Project Grant. BUTLER LM, Lynn DJ, Hayes VM, Horvath LG, Mills IG and Centenera MM. Novel co-extinction strategies for treatment of prostate cancer. 2017-2021. $596,409.
  • Cancer Australia Project Grant. BUTLER LM, Horvath LJ, Tilley WD, Stocker M, Stricker PD and Kench JD. A randomised controlled Phase II trial of the pharmacodynamic effects of the Cdk4/6 inhibitor, LEE011, in high-risk, localised prostate cancer. 2016-2020. $590,408.
  • Movember Foundation / Prostate Cancer Foundation of Australia Revolutionary Team Award. BUTLER LM, Swinnen JV, Tilley WD, Scott AM, Hoy AJ and Wittert GA. Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer. Phase 1: 2015-2018. $3,250,000. Phase 2: 2019-2021. $2,000,000.

 

PREVIOUS GRANTS

  • Prostate Cancer Foundation of Australia Novel Concept Grant. BUTLER LM and Voelcker N. Next-generation prostate cancer therapies based on precision nanomedicines. 2017-2018. $99,919.
  • Cancer Australia Project Grant. BUTLER LM, Daly R, Tilley WD, Horvath LG and Centenera MM. Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer. 2015-2018. $553,483.
  • NHMRC Development Grant. Brooks DA, BUTLER LM and O’Leary JJ. Development of effective biomarkers for the diagnosis and prognosis of Prostate Cancer. 2015-2017. $1,029,873.
  • Cancer Australia Project Grant. Tilley WD, BUTLER LM, Plymate S and Selth LA. Mechanism and targeting of castration resistant prostate cancer. 2013-2015. $586,398.
  • Ray and Shirl Norman Cancer Research Trust Research Grant. Tilley WD, BUTLER LM, Selth LA and Parnis F. Targeting androgen receptor variant signalling in lethal prostate cancer. 2013-2014. $327,184.
  • Royal Adelaide Hospital Clinical Project Grant. Centenera MM and BUTLER LM. Evaluation of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2013. $48,000.
  • Royal Adelaide Hospital Clinical Project Grant. BUTLER LM, Brook N, Sutherland P and Saunders P.  Development of an Australian prostate cancer reference cohort to support research identifying better biomarkers that predict disease progression. 2013. $18,000.
  • Prostate Cancer Foundation of Australia New Directions Development Award. BUTLER LM, Centenera MM, Claessens F and Swinnen JV. Exploiting metabolic alterations to more accurately monitor prostate cancer therapy. 2012-2013. $299,817.
  • Cancer Australia Project Grant. Tilley WD, BUTLER LM, Hoffman P, Goodall G and Scher HI. A novel approach to predict metastatic potential at prostate cancer diagnosis. 2011-2013. $591,732.
  • Prostate Cancer Foundation of Australia Project Grant. Buchanan G, Kee T and BUTLER LM. Targeting chemokine signalling in prostate cancer. 2011-2012. $250,000.
  • RAH/IMVS Research Committee Clinical Project Grant. Centenera MM, BUTLER LM and Tilley WD. Identification of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2011. $20,000.
  • Cancer Australia/Prostate Cancer Foundation of Australia Project Grant. BUTLER LM, Tilley WD and Scher HI. A combinatorial approach targeting androgen signalling for treatment of prostate cancer. 2010-2012. $589,673.
  • NHMRC Project Grant. Tilley WD, BUTLER LM, Scher H and Bianco-Miotto T. The essential role of androgen receptor signalling in prostate tumorigenesis. 2010-2012. $813,913.
  • RAH/IMVS Research Committee Clinical Project Grant. BUTLER LM. A novel explant model for the investigation of hormone signalling and novel treatments in human prostate tissue. 2010. $20,000.
  • NHMRC Project Grant. Evdokiou A, Findlay DM and BUTLER LM. Histone Deacetylase Inhibitors (HDIs) with antineoplastic and antiosteolytic properties. 2008-2010. $513,750.
  • US Army Medical Research and Material Command Congressionally Directed Medical Research Programs.  Tilley WD, BUTLER LM and Marshall VR. Mechanism of Prostate Cancer Tumorigenesis. 2007-2010. $USD 482,622.
  • NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling in development and progression of prostate cancer. 2007-2009. $723,750.
  • National Breast Cancer Foundation of Australia. Androgen receptor status as a determinant of breast cancer risk. Tilley WD, BUTLER LM, Roder DM and Gelareh F. 2007-2008. $168,000.
  • US Army Medical Research and Material Command Congressionally Directed Medical Research Programs.  Kennaway DJ, Tilley WD and BUTLER LM. Disruption of the circadian rhythms of gene expression and the development of breast cancer. 2006-2008. $USD 381,818.
  • National Breast Cancer Foundation of Australia. Evdokiou A, BUTLER LM and Findlay DM. TRAIL in breast cancer therapy. 2006-2008. $254,004.
  • Cancer Council of South Australia. Tilley WD, BUTLER LM, Roder D and Farshid G. Androgen receptor status as a determinant of breast cancer risk. 2006. $76,000.
  • The Susan G Komen Breast Cancer Foundation. BUTLER LM, Tilley WD and Birrell SN. Role of androgen signalling in the breast: disruption by synthetic progestins. 2005-2008. $USD 333,332.
  • Cancer Council of South Australia. Evdokiou A, BUTLER LM and Findlay DM. Inhibition of breast cancer growth in, and metastasis to, bone using TRAIL therapy. 2005. $64,125.
  • NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling and progression of prostate cancer. 2004-2006. $455,250,
  • US Army Medical Research and Materiel Command, Breast Cancer Research Program. Kennaway DJ, BUTLER LM and Tilley WD. Clock genes: critical modulators of breast cancer risk? 2004-2005. $USD 99,485.
  • US Army Medical Research and Materiel Command. Tilley WD, BUTLER LM and Birrell SN. The role of androgen receptor signalling in breast cancer. 2003-2006. $USD 350,121.
  • NHMRC Project Grant. Tilley WD, BUTLER LM and Birrell SN. Inhibition of estrogen signalling by the androgen receptor: a potential mechanism of suppression of breast cancer cell growth by androgens. 2003-2005. $375,000.

 

PREVIOUS COMMERCIAL FUNDING

  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Morrow I, Chappell N, Moore C, Reynolds P, Esterman A, Karageorgos L. Development Program: Biomarkers and therapeutics for prostate and other cancers. 2020. $2,000,000.
  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Reynolds P, Esterman A, Olver I. Companion diagnostics and therapeutics for cancer. 2019. $2,350,000.
  • AusHealth Project Grant. BUTLER LM, Ranieri E. Lipid screening for prostate cancer prognosis. 2018-2020. $200,000.
  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, Plush S, Massi M, Brooks RD, O’Leary JJ, BUTLER L, Sorvina A, Bader C. Visualising the pathogenesis in cancer and developing novel therapeutics. 2017-2018. $1,019,225.
  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, BUTLER L, Johnson I, Selemidis S, Parkinson-Lawrence EJ, Sorvina A, Olver I, Esterman A. Prostate cancer diagnosis and prognosis. 2017-19. $2,930,165.

 

EQUIPMENT FUNDING

  • Australian Cancer Research Foundation. Hughes TP, Zannettino ACW, White DL, Proud CG, Wesselingh SL, Lynn DJ, BUTLER LM, Gronthos S, Tilley WD and Bulone V. ACRF Centre for Integrated Cancer Systems Biology. 2018-2022. $2,500,000.

 

In addition to her extensive supervision of post-graduate students, Prof Butler has several roles in undergraduate teaching at The University of Adelaide.

 

LECTURING

  • Biochemistry III – 3 lectures/year (2016-present)
  • Masters of Biotechnology (Biomedical) – 1 lecture/year (2014-2017)
  • Comparative Reproductive Biology of Mammals III - 1 lecture/year (2011-2017)
  • Structural Cell Biology III – 6 lectures/year (2011-2016)

 

LABORATORY SUPERVISION

  • Laboratory-based research projects as part of Level 3 Physiology and Medical Science, and Level 3 Biochemistry (2003-present)
  • Summer vacation projects and scholarship program (2003-present)

 

STATE-WIDE RESEARCH TRAINING

  • Teaching of annual workshop on Human Ethics for Laboratory Research- provided to all higher degree research students from the University of Adelaide, UniSA and Flinders University of SA (2009-2012)
    Expand
  • Current Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2021 Co-Supervisor Overcoming resistance to cyclin-dependent kinase inhibition in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Joshua Thomas Hodgson
    2020 Principal Supervisor The role of Mitofusin-2 in prostate cancer Master of Philosophy (Medical Science) Master Full Time Miss Elizabeth Hannah Collis
    2020 Principal Supervisor Lipid imaging in prostate cancer tissue. Master of Philosophy (Medical Science) Master Full Time Mr Jacob Truong
    2020 Co-Supervisor Targeting Lipid Metabolism in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Deanna Catherine Miller
    2019 Principal Supervisor Androgen Regulation of Lipid Metabolism Doctor of Philosophy Doctorate Full Time Miss Julia Steele Scott
    2019 Co-Supervisor Elucidating the Interplay Between Androgen Receptor Signalling and Lipid Metabolism in Prostate Cancer Doctor of Philosophy Doctorate Full Time Ms Meiwen Danielle Fang
    2018 Principal Supervisor Androgen-Regulated Drivers of Prostate Tumorigenesis Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Miss Josephine Ataa Hinneh
    2018 Principal Supervisor Targeting Polyunsaturated Fatty Acid Metabolism in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Chui Yan Mah
  • Past Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2018 - 2021 Principal Supervisor Investigating the Contribution of Specific Cancer-Associated Fibroblast Subsets to Colorectal Tumourigenesis Doctor of Philosophy Doctorate Full Time Miss Krystyna Anna Gieniec
    2017 - 2021 Co-Supervisor Elucidating the molecular mechanisms underlying androgen-regulated lipid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Raj Kumar Shrestha
    2016 - 2019 Principal Supervisor Defining the Role of Lipids and Metabolic Factors as Risk Factors for Prostate Cancer Incidence and Aggressiveness Doctor of Philosophy Doctorate Full Time Dr Adel Tahseen Abdelhamid Aref
    2016 - 2020 Principal Supervisor Understanding the Role of Androgen Receptor Signalling in Prostate Cancer:
    A Lipidomics Approach by MALDI Mass Spectrometry Imaging
    Doctor of Philosophy Doctorate Full Time Mr Shadrack Mulinge Mutuku
    2013 - 2016 Principal Supervisor Elucidating the Molecular Action of Synthetic Heat Shock Protein 90 Inhibitors in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Heather Krista Armstrong
    2013 - 2016 Co-Supervisor The Role of microRNA-194 and microRNA-375 in Prostate Cancer Metastasis Doctor of Philosophy Doctorate Full Time Dr Rajdeep Das
    2008 - 2011 Co-Supervisor Investigating Lymphatic Vascular Remodelling During Postnatal Mouse Mammary Gland Morphogenesis Doctor of Philosophy Doctorate Full Time Ms Kelly Louise Betterman
    2007 - 2015 Principal Supervisor Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy Doctor of Philosophy Doctorate Full Time Miss Sarah Carter
    2006 - 2010 Co-Supervisor The Role of Epigenetic Modifications in Prostate Tumourigenesis Doctor of Philosophy Doctorate Full Time Ms Karen Huiqin Chiam
    2004 - 2008 Co-Supervisor Characterisation of a Dominant Negative Androgen Receptor in Prostate Cancer Cells Doctor of Philosophy Doctorate Part Time Dr Margaret Centenera
    2004 - 2008 Principal Supervisor Androgen Signalling in Normal and Malignant Breast Epithelial Cells Doctor of Philosophy Doctorate Part Time Ms Amelia Peters
    2003 - 2007 Co-Supervisor Targeting the Androgen Receptor as a Therapeutic Strategy for Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Deborah Marrocco
  • Other Supervision Activities

    Date Role Research Topic Location Program Supervision Type Student Load Student Name
    2020 - ongoing Co-Supervisor A comprehensive assessment of cancer cell metabolism University of Sydney Doctorate Nancy Santiappillai
    Expand
  • Committee Memberships

    Date Role Committee Institution Country
    2021 - ongoing Chair Australian Prostate Cancer BioResource Executive Committee Australian Prostate Cancer BioResource Australia
    2021 - ongoing Chair Research Committee Prostate Cancer Foundation of Australia Australia
    2021 - ongoing Board Member National Board of Directors Prostate Cancer Foundation of Australia Australia
    2020 - ongoing Member ANZUP Cancer Trials Group, Scientific Advisory Committee Australian and New Zealand Urogenital and Prostate (ANZUP) Australia
    2018 - ongoing Chair BROCADE Tissue Access Committee Chair National Breast Cancer Foundation Australia
    2017 - ongoing Member Research Advisory Committee Prostate Cancer Foundation of Australia Australia
    2016 - ongoing Member Faculty of Health Sciences Research Committee The University of Adelaide Australia
    2016 - ongoing Member Genomics Executive Committee South Australian Health and Medical Research Institute Australia
    2015 - ongoing Member Appointments Committee South Australian Health and Medical Research Institute Australia
    2014 - 2015 Chair School of Medicine Research Committee The University of Adelaide Australia
    2013 - ongoing Member ANZUP Cancer Trials Group, Prostate and Translational Sub-Committee Australian and New Zealand Urogenital and Prostate (ANZUP) Australia
    2012 - ongoing Member NHMRC Research Translation Faculty National Health and Medical Research Council Australia
    2012 - ongoing Member Australian Prostate Cancer Research - Scientific Member Australian Prostate Cancer Research Australia
    2012 - 2015 Member NHMRC Postdoctoral Reference Group National Health and Medical Research Council Australia
    2012 - ongoing Convener Australian Prostate Cancer BioResource Executive Committee, Adelaide Node Coordinator Australian Prostate Cancer BioResource Australia
    2011 - ongoing Member Freemasons Foundation Centre for Men's Health Executive Committee The University of Adelaide Australia
    2011 - ongoing Member Movember Global Action Plan for Prostate Cancer - Functional Group Leader Movember Australia
    2009 - ongoing Member Postgraduate Coordinator, Adelaide Medical School The University of Adelaide Australia
    2009 - ongoing Member Australian Prostate Cancer BioResource Executive Committee Australian Prostate Cancer BioResource Australia
    2007 - 2009 Member Institutional Biosafety Committee Institute of Medical and Veterinary Science Australia
    2006 - 2013 Member School of Medicine Research Committee The University of Adelaide Australia
    2004 - 2009 Member Institutional Biosafety Committee The University of Adelaide Australia
    2003 - 2010 Member South Australian Breast Cancer Study Group Executive South Australian Breast Cancer Study Group Australia
    2003 - 2005 Board Member Australian Society for Medical Research Australian Society for Medical Research Australia
  • Memberships

    Date Role Membership Country
    2020 - ongoing Member Society for Basic Urological Research United States
    2012 - ongoing Member Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Australia
    2011 - ongoing Member Centre for Personalised Cancer Medicine - University of Adelaide Australia
    2006 - ongoing Member Hanson Institute Australia
    2006 - ongoing Member Endocrine Society United States
    2006 - ongoing Member Endocrine Society of Australia Australia
    2004 - ongoing Member South Australian In Vivo Mouse Models Network Australia
    2001 - ongoing Member Australian Prostate Cancer Collaboration Australia
    1999 - ongoing Member American Association for Cancer Research United States
    1995 - ongoing Member Australian Society for Medical Research Australia
  • Community Engagement

    Date Title Engagement Type Institution Country
    2020 - ongoing Updates in prostate cancer research Public Community Engagement Mount Barker Prostate Cancer Support Group Australia
    2020 - ongoing Overloading fats in prostate cancer cells is key to destroying them say researchers Public Community Engagement The Senior (online publication) Australia
    2020 - ongoing Radio interview Public Community Engagement 5AA Adelaide Australia
    2020 - ongoing Fat can kill cancer cells Public Community Engagement The Adelaide Advertiser (newspaper) Australia
    2020 - ongoing Researcher Showcase Discussion Panel (Public Event) Public Community Engagement Cancer Council SA Australia
    2019 - ongoing Working Together to Combat a Killer Public Community Engagement The Adelaide Advertiser (newspaper) Australia
    2018 - ongoing Taking the Fight to Cancer Public Community Engagement The Adelaide Advertiser (newspaper)
    2018 - ongoing Defining Future Cancer Treatments, promotional video Public Community Engagement The University of Adelaide Australia
    2017 - ongoing Lipids, obesity and prostate cancer Public Community Engagement Wealth and Wellbeing SAHMRI initiative launch for Bell Potter Securities Australia
    2017 - ongoing Improving diagnosis, treatment and molecular imaging of prostate cancer Public Community Engagement SAHMRI Public Lecture Series - Cancer: Prevention, Diagnosis and Treatment (Public Event) Australia
    2017 - ongoing New diagnosis and treatment tools for prostate cancer Public Community Engagement Lions Club Annual Meeting, Adelaide Australia
    2017 - ongoing Networking advice for junior scientists Scientific Community Engagement Australian Society for Medical Research, Networking Event Australia
    2016 - ongoing New markers for diagnosing prostate cancer Public Community Engagement Prostate Cancer Foundation of Australia Community Conversations (Public Event) Australia
    2015 - ongoing Radio interview Public Community Engagement 5AA Adelaide
    2015 - ongoing Radio interview Public Community Engagement ABC Radio Adelaide Australia
    2015 - ongoing Lipids, obesity and prostate cancer Public Community Engagement North Shore Prostate Cancer Support Group Australia
    2015 - ongoing Prostate hope in pioneer test Public Community Engagement The Adelaide Advertiser (newspaper) Australia
    2015 - ongoing Working overseas to build your CV and future career Scientific Community Engagement Australian Society for Medical Research, Networking Event Australia
    2015 - ongoing World-first Cancer Research Public Community Engagement The Adelaide Review (newspaper) Australia
    2015 - ongoing Radio interview Public Community Engagement ABC Adelaide radio Australia
    2015 - ongoing Associate Professor Lisa Butler assembles world class team in bid to develop new biomarkers Public Community Engagement Prostate News (magazine) Australia
    2014 - ongoing International research team formed to make impact on clinical care for prostate cancer patients Public Community Engagement The Lead SA (online newspaper) Australia
    2014 - ongoing Prostate Team’s $3m Aim Public Community Engagement The Adelaide Advertiser (newspaper) Australia
    2014 - ongoing Radio interview Public Community Engagement ABC Radio Adelaide Australia
    2014 - ongoing Challenges in prostate cancer research (lay presentation) Public Community Engagement Royal Adelaide Hospital Australia
    2014 - ongoing Public laboratory tours Public Community Engagement South Australian Health and Medical Research Institute Australia
    2014 - ongoing Regular Consumer Advisory Group Meetings Public Community Engagement The University of Adelaide Australia
    2012 - ongoing Radio interview Public Community Engagement 5AA Adelaide Australia
    2012 - ongoing Challenges in prostate cancer research - Research Tuesday Public Lecture Series Public Community Engagement The University of Adelaide Australia
    2012 - ongoing Towards improved management of breast and prostate cancer Public Community Engagement Cancer Care EXPO (Public Event) Australia
    2011 - ongoing Probing the causes and treatment of prostate cancer Public Community Engagement Toshiba Medical presentation to radiology professionals Australia
    2008 - ongoing Television news story Public Community Engagement Channel 9 Adelaide Australia
  • Editorial Boards

    Date Role Editorial Board Name Institution Country
    2020 - ongoing Associate Editor Frontiers in Endocrinology - Systems Endocrinology Frontiers in Endocrinology United States
    2019 - ongoing Board Member Journal of the National Cancer Institute Journal of the National Cancer Institute United States
    2015 - ongoing Board Member Frontiers in Endocrinology Frontiers in Endocrinology United States
    2015 - ongoing Board Member Frontiers in Oncology Frontiers in Oncology United States
  • Review, Assessment, Editorial and Advice

    Date Title Type Institution Country
    2021 - ongoing Grant Review Grant Assessment European Science Foundation
    2020 - ongoing Grant Review Grant Assessment Swiss National Science Foundation Switzerland
    2019 - ongoing Grant Review Grant Assessment Australia-India Strategic Research Fund Australia
    2018 - ongoing Grant Review Grant Assessment ANZUP Below the Belt Fund Australia
    2017 - ongoing Grant Review Grant Assessment Cancer Institute of NSW Australia
    2017 - ongoing Grant Review Grant Assessment Prostate Cancer UK United Kingdom
    2015 - ongoing Grant Review Grant Assessment Cancer Research UK United Kingdom
    2015 - ongoing Grant Review Grant Assessment Cure Cancer Australia Australia
    2015 - ongoing Research Advisory Committee Grant Assessment Prostate Cancer Foundation of Australia Australia
    2015 - ongoing Grant Review Panel Grant Assessment Health Research Council of New Zealand New Zealand
    2013 - ongoing Early Career Fellowships Review Panel Grant Assessment National Breast Cancer Foundation Australia
    2012 - ongoing Grant Review Grant Assessment Cancer Council Australia
    2012 - ongoing Grant Review Grant Assessment Prostate Cancer Foundation of Australia Australia
    2012 - ongoing Grant Review Grant Assessment National Breast Cancer Foundation Australia
    2011 - ongoing Grant Review Panel Grant Assessment Cancer Australia Australia
    2010 - ongoing Oncology Grant Review Panels Grant Assessment National Health and Medical Research Council Australia
    2005 - ongoing Grant Review Grant Assessment National Health and Medical Research Council Australia
  • Position: Cancer Council Principal Research Fellow
  • Phone: 81284360
  • Email: lisa.butler@adelaide.edu.au
  • Campus: North Terrace
  • Building: SAHMRI - Prostate Cancer Research Group, floor 5
  • Org Unit: Medical Specialties

Connect With Me
External Profiles

Other Links